United States, March 10 -- The U.S. Food and Drug Administration announced another major step in its initiative to streamline the development of biosimilar medicines, which are like "generic" versions of biologic drugs. In new draft guidance issued today, the agency recommended streamlining unnecessary clinical pharmacokinetic (PK) testing when scientifically justified. This change could save biosimilar developers up to 50% of their PK study costs, or approximately $20 million, and help lower drug costs. Biologic medicines can be powerful treatments for many diseases, including autoimmune diseases and cancer, but are often expensive. Despite accounting for just 5% of prescriptions, biologics account for 51% of drug spending, and commonly co...